|
James Graham Brown Endowed Chair; Professor of Medicine; Director, James Graham Brown Cancer Center; Advisory Director, University Medical Center, Inc. Board
MultidisciplinarySkin/Melanoma
Research ProgramMolecular Targets
Clinical ExpertiseHead and Neck
Medical Oncology
Skin Cancer/Melanoma
EducationB.S., Florida State University, Tallahassee, FL, Chemistry, 1967
Ph.D., Duke University, Durham, NC, Biochemistry, 1972
Post-Doctoral Fellow, Duke University, Durham, NC, Biochemistry, 1972
M.D., Duke University, Durham, NC, Medicine, 1973
Research and Professional Experience
1973-1974
Intern, Peter Bent Brigham Hospital, Boston, MA
1974-1975
Assistant Resident in Medicine, Peter Bent Brigham Hospital, Boston, MA
1975-1978
Clinical Fellow in Medicine, Harvard University, Boston, MA
1978-1979
Sr Staff Associate (Clinical Fellow), NCI, VA Medical Oncology Branch, Washington, DC
1979-1984
Assistant Professor, Department of Internal Medicine, University of Michigan, Ann Arbor
1984-1988
Associate Professor, Departments of Internal Medicine and Biochemistry; Scientist, Comprehensive Cancer Center, University of Alabama at Birmingham (UAB)
1984-1999
Director, Human Molecular Biology Group, Comprehensive Cancer Center, UAB
1986-1988
National Program Specialist in Oncology, VA Research Administration
1986-1991
Clinical Investigator, VA Career Development Program
1988-1992
Member, Hematology-2 Study Section, National Institutes of Health
1988-1999
Professor, Departments of Internal Medicine and Biochemistry; Senior Scientist, CCC, UAB
1990-1997
Director, Division of Hematology/Oncology, UAB
1990-1999
Deputy Director, Comprehensive Cancer Center, UAB
1995
Elected, American Association of Physicians
1999-present
Director, James Graham Brown Cancer Center, University of Louisville School of Medicine
1999-present
Professor, Internal Medicine and Pharmacology, University of Louisville School of Medicine
1999-present
James Graham Brown Professor of Oncology, University of Louisville School of Medicine
2000-2002
Chairman, Hematology-2 Study Section, National Heart, Lung & Blood Institute, NIH
2007-present
Advisory Director, University Medical Center, Inc. Board
Selected Awards and Professional Honor
1982-87
Scholar, Leukemia Society of America
1988-92
Councilor, Southern Society of Clinical Investigation
1992-95
Secretary Treasurer, Southern Society of Clinical Investigation
1995
President, Southern Society of Clinical Investigation
1988-92
Chairman, Scientific Advisory Board, Clinical Research Center, UAB
1992
Fellow, Royal Society of Medicine, London
1994
H. & M. Holley Research Prize, American College of Rheumatology
1998
Named to Best Doctors in America
2000
Recipient, Founders Medal, Southern Society of Clinical Investigation
2000-2003
Member, State of Kentucky Lung Cancer Research Committee
2000-2002
Member, Executive Committee Susan G. Komen Foundation
2003
Mint Jubilee Lifetime Achievement Award
PublicationsSubramanian A, Miller DM. Structural analysis of alpha-enolase. Mapping the functional domains involved in down-regulation of the c-myc protooncogene. J Biol Chem 275:5958-65, 2000
Vigneswaran N, Zhao W, Dassanayake A, Muller S, Miller DM, Zacharias W. Variable expression of cathepsin B and D correlates with highly invasive and metastatic phenotype of oral cancer. Hum Pathol 31:931-7, 2000
Vigneswaran N, Thayaparan J, Knops J, Trent J, Potaman V, Miller DM, Zacharias W. Intra- and intermolecular triplex DNA formation in the murine c-myb proto-oncogene promoter are inhibited by mithramycin. Biol Chem 382:329-42, 2001
Xu X, Hamhouyia F, Thomas SD, Burke T, Girvan AC, McGregor WG, Trent JO, Miller DM, Bates PJ. Inhibition of DNA replication and induction of S phase cell cycle arrest by G-rich oligonucleotides. J Biol Chem 276:43221-30, 2001
Dapic V, Bates PJ, Trent JO, Rodger A, Thomas SD, Miller DM. Antiproliferative activity of G-quartet-forming oligonucleotides with backbone and sugar modifications. Biochemistry 41:3676-85, 2002
Mi Y, Thomas SD, Xu X, Casson LK, Miller DM, Bates PJ. Apoptosis in leukemia cells is accompanied by altera-tions in the levels and localization of nucleolin. J Biol Chem 278:8572-79, 2003
Kakar SS, Winters SJ, Zacharias W, Miller DM, Flynn S. Identification of distinct gene expression profiles associa-ted with treatment of LbetaT2 cells with gonadotropin-releasing hormone agonist using microarray analysis. Gene 308:67-77, 2003.
Blume SW, Miller DM, Guarcello V, Shrestha K, Meng Z, Snyder RC, Grizzle WE, Ruppert JM, Gartland GL, Stockard CR, Jones DE, Emanuel PD. Inhibition of tumorigenicity by the 5'-untranslated RNA of the human c-myc P0 transcript. Exp Cell Res. 288:131-42, 2003.
Meng Z, Snyder RC, Shrestha K, Miller DM, Emanuel PD, Blume SW. Evidence for differential ribonucleoprotein complex assembly in vitro on the 5'-untranslated region of the human IGF-IR transcript. Mol Cell Endocrinol. 200:127-40, 2003
Laber DA, Okeke RI, Arce-Lara C, Taft BS, Schonard CL, McMasters KM, Kloecker GH, Miller DM. A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma. J Cancer Res Clin Oncol 132(9):611-6, 2006
Sedoris KC, Thomas SD, Miller DM. c-myc promoter binding protein regulates the cellular response to an altered glucose concentration. Biochemistry 46(29):8659-68, 2007
Garbett NC, Miller JJ, Jenson AB, Miller DM, Chaires JB. Interrogation of the plasma proteome with differential scanning calorimetry. Clin Chem 53(11):2012-4, 2007
Rasku MA, Clem AL, Telang S, Taft B, Gettings K, Gragg H, Cramer D, Lear SC, McMasters KM, Miller DM, Chesney J. Transient T cell depletion causes regression of melanoma metastases. J Transl Med 11;6:12, 2008
Courtenay-Luck N, Miller DM. AS1411: Development of an anticancer aptamer in therapeutic oligonucleotides. RSC Publishing, Royal Society of Chemistry, London, 2008
Lane AN, Fan TW, Higashi RM, Tan J, Bousamra M, Miller DM. Prospects for clinical cancer metabolomics using stable isotope tracers. Exp Mol Pathol 86(3):165-173, 2009
Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 86(3):151-164, 2009
Jaglal MV, Laber DA, Arnold FW, Miller DM, Chesney JA, Kloecker GH. Obtaining routine nlood cultures during interleukin-2-containing therapy is unnecessary. Am J Clin Oncol 2009 May 15. [Epub ahead of print] PMID: 19451801
Khan MI, Chesney JA, Laber DA, Miller DM. Digitalis, a targeted therapy for cancer? Am J Med Sci 337(5):355-9, 2009
Fan TW, Lane AN, Higashi RM, Bousamra M 2nd, Kloecker G, Miller DM. Metabolic profiling identifies lung tumor responsiveness to erlotinib. Exp Mol Pathol 2009 May 3. [Epub ahead of print]
Desai PC, Jaglal MV, Gopal P, Ghim SJ, Miller DM, Farghaly H, Jenson AB. Human papillomavirus in metastatic squamous carcinomas from unknown primaries: A retrospective 7 year study. Exp Mol Pathol 2009 Apr 22. [Epub ahead of print]
Lane AN, Fan TW, Higashi RM, Tan J, Bousamra M, Miller DM. Prospects for clinical cancer metabolomics using stable isotope tracers. Exp Mol Pathol 86(3):166-73, 2009; PMC2685876. Review.
Fan TW, Lane AN, Higashi RM, Farag MA, Gao H, Bousamra M, Miller DM. Altered regulation of metabolic pathways in human lung cancer discerned by 13C stable isotope-resolved metabolomics (SIRM). Mol Cancer 8(1):41, 2009
Related Stories
Contact InfoAdministration Offices, James Graham Brown Cancer Center
529 South Jackson Street
Louisville, KY 40202
Phone: Academic office: (502) 562-4790
Appointments: (502) 589-4856
Fax: (502) 562-4368
|
|